


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-2.62%
+1.09%
-11.46%
+0.27%
PROF
Profound Medical Cor
$7.50
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
PROF Price Performance
$7.77 (-3.47%)
$5.9 (+27.12%)
$3.87 (+93.80%)
$6.79 (+10.46%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Earnings decline YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
PROF Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PROF Street Sentiment is extremely bullish and have positive views on the near-term outlook
PROF has Low risk level
Risks Indicators

Low volume

Average key support and resistance price levels
Recent Upgrades and Downgrades
STRONG BUY
Date
Action
Rating
Firm
Nov 19, 2025
Upgrade
Buy
Zacks
SYK
Stryker
369.56
+4.27%
MMSI
Merit Medical System
81.09
+1.06%
IINN
Inspira Technologies Oxy
0.75
-3.85%
BSX
Boston Scientific
93.53
+1.30%
PROF
Profound Medical Cor
7.50
+0.27%
BTCS
BTCS
2.24
-11.46%
ANVS
Annovis Bio
2.70
-5.45%
MOLN
Molecular Partners AG
4.25
+2.29%
ABCB
Ameris Bancorp
80.62
-0.84%
What is PROF current stock price?
What are PROF stock strengths?
What is PROF Risk Level?
What is PROF market cap and volume?
What is PROF current Stock IQ?
Should I buy PROF stock right now?
Is PROF a Strong Buy right now?
What does a 'Strong Buy' rating mean for PROF?
What does a 'Strong Sell' rating mean for PROF?
What factors influence PROF's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.62%
+1.09%
-11.46%
+0.27%
PROF
Profound Medical Cor
Current Price
$7.50
Linked to PROF
SYK
Stryker
369.56
+4.27%
MMSI
Merit Medical System
81.09
+1.06%
IINN
Inspira Technologies Oxy
0.75
-3.85%
BSX
Boston Scientific
93.53
+1.30%
Recently Viewed
PROF
Profound Medical Cor
7.50
+0.27%
BTCS
BTCS
2.24
-11.46%
ANVS
Annovis Bio
2.70
-5.45%
MOLN
Molecular Partners AG
4.25
+2.29%
ABCB
Ameris Bancorp
80.62
-0.84%

PROF Price Performance
$7.77 (-3.47%)
$5.9 (+27.12%)
$3.87 (+93.80%)
$6.79 (+10.46%)
PROF Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Earnings decline YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
PROF Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PROF Street Sentiment is extremely bullish and have positive views on the near-term outlook
PROF has Low risk level
Risks Indicators

Low volume

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Nov 19, 2025
Upgrade
Buy
Zacks
PROF Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
PROF Latest Analysis
Profound Medical (PROF) Soars 9.5%: Is Further Upside Left in the Stock?. Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesnt suggest further strength down the road.
Fri Jan 16, 2026
Mindbody Parent Playlist Merges With EGYM in $7.5B Deal. agreed to merge with global smart-fitness leader While closing of this transaction is subject to customary regulatory approvals the includes $785 million in new equity investments putting the joint venture at $7.5 billion the statement said. This venture is led by Affinity Partners Vista Equity Partners Temasek and L Catterton.Playlist’.s brands will continue to operate business as usual following the closing of the transaction. Meanw
Thu Jan 15, 2026
CMO Council Marks 25th Anniversary In 2026 With Expert Views On Evolutionary Role Of Chief Marketing Officer In C-Suite. SAN JOSE Calif. Jan. 14 2026 (GLOBE NEWSWIRE) -- The CMO Council'.s for 2026 reflects on 25 years of an evolving and defining role for the chief marketing officer in the C-Suite. The elite executive affinity network of some 20000 global marketing leaders controlling nearly $1 trillion of annual spend emphasizes that CMOs today are no longer expected to simply build brands
Wed Jan 14, 2026
YDES: YD Bio is an integrated biotechnology company that is poised to have a transformational year as it expands business operations.. By YD Bio (NASDAQ:YDES) is an integrated biotechnology company that combines diagnostics precision medicine and regenerative ophthalmology under a single commercial and development strategy. The companys mission centers on early cancer detection using blood-based diagnostic tests the development of exosome-based therapeutics and tools for ophthalmic conditions an
Tue Jan 13, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
PROF Stock trends
PROF Stock performance
PROF Stock analysis
PROF investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.